The immunopeptidome is the set of peptides presented by the major histocompatibility
complex (MHC) molecules, in humans also known as the human leukocyte antigen (HLA) …

Activating RAS missense mutations are among the most prevalent genomic alterations
observed in human cancers and drive oncogenesis in the three most lethal tumor types …

Infectious diseases are commonly implicated as potential initiators of autoimmune diseases
(ADs) and represent the most commonly known factor in the development of autoimmunity in …

Serial multi-omic analysis of proteome, phosphoproteome, and acetylome provides insights
into changes in protein expression, cell signaling, cross-talk and epigenetic pathways …

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly
because of the lack of actionable immune targets. Using an original proteogenomic …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Different strategies based on peptides are available for cancer treatment, in particular to
counter-act the progression of tumor growth and disease relapse. In the last decade, in the …

Immunopeptidomics is crucial for immunotherapy and vaccine development. Because the
generation of immunopeptides from their parent proteins does not adhere to clear-cut rules …

Studies have characterized the immune escape landscape across primary tumors. However,
whether late-stage metastatic tumors present differences in genetic immune escape (GIE) …

Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed
in cancer cells. These highly immunogenic antigens may trigger the immune system to …